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Care of acute conditions and chronic diseases in Canada and the United
States: Rapid systematic review and meta-analysis
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1School
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Introduction

Significance for public health

Canadians and Americans rate health care a top concern. They
seem naturally to wonder if health care policies are greener on the
other side of their unfenced 5,000-kilometer border. Some
Americans − particularly concerned with health care inaccessibility among the uninsured − have called for a more Canada-like single payer system. In contrast, some Canadians − concerned with
health care shortages − have called for a more American-like system with more private options. Aiming to contribute critical evidence to these debates, our research group has focused on the
health care of people living in poverty. We assume that this magnifies human and policy significance.
Canada-USA comparative studies of health care among overall populations can be misleading. For example, the first study to
compare Canada and the USA on cancer survival − a 1994 USA
General Accounting Office study − observed no practically significant between-country differences.1 Not accounting for socioeconomic factors, its null findings were not surprising as gross comparisons of diverse national haystacks will necessarily lose important needles of knowledge. Consider the great diversity of people
and places in Canada and the USA: women and men, the uninsured to the well-insured, recently emigrated ethnic minority people of color to European white people who landed generations
ago, residents of megalopolises to remote places, high poverty to
affluent neighborhoods and so on. Any study of diverse national
populations that merely reports an average effect will miss knowledge about the unique experiences of important subpopulations.
Alternatively, our research group’s study of cancer survival among
the poor in Toronto, Ontario and Detroit, Michigan during the
same era found substantially higher survival rates among
Canadians.2 Though geographically limited, it suggested that this
field’s scholars and policy makers ought to include socioeconomic
factors in their designs and decisions.
Joint Canada/USA surveys have consistently demonstrated
greater income-related health, health care and mortality disparities
in the USA.3-5 Similar surveys of the poor in each country found
them to be healthier and with greater health care access in
Canada.6,7 With unanimity, these studies advanced universal, single payer health insurance coverage as a key explanation for
Canadian advantages. Notwithstanding cross-sectional limitations, they essentially developed a health insurance hypothesis
that others have tested with more rigorous, longitudinal methods
over a generation. The findings of 64 such Canada-USA longitudinal comparative outcome studies published between 1965 and
2000 were synthesized between 1999 and 2009 in two systematic
reviews of diverse health outcomes and a meta-analysis of breast
cancer survival.8-10
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This study estimated that socioeconomically vulnerable Canadians’ chances
of receiving better health care were 36% greater than their American counterparts and this estimate was larger than that based on general patient
comparisons (9%). One may wonder about the public health significance of
such relative risks/protections. Attributions of risk/protection among populations are a function of three factors of which relative risk is only one. The
size of the population and the prevalence of exposure to risks are also important. In this instance, the entire USA population is at relatively greater risk
of receiving lower quality care, its more prevalent low-income and inadequately insured populations more so. Applying our findings to population
parameters and attributable risk formulations we estimated that without
reform, over the next generation more than 50 million Americans will be
treated less optimally and die earlier than had they enjoyed a single-payer
health care system like Canada’s.
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This study tested the hypothesis that socioeconomically vulnerable Canadians with diverse acute conditions or chronic diseases have health care access and survival advantages over their
counterparts in the USA. A rapid systematic review retrieved 25
studies (34 independent cohorts) published between 2003 and
2018. They were synthesized with a streamlined meta-analysis.
Very low-income Canadian patients were consistently and highly
advantaged in terms of health care access and survival compared
with their counterparts in the USA who lived in poverty and/or
were uninsured or underinsured. In aggregate and controlling for
specific conditions or diseases and typically 4 to 9 comorbid factors or biomarkers, Canadians’ chances of receiving better health
care were estimated to be 36% greater than their American counterparts (RR=1.36, 95% CI 1.35-1.37). This estimate was significantly larger than that based on general patient or non-vulnerable
population comparisons (RR=1.09, 95% CI 1.08-1.10). Contrary
to prevalent political rhetoric, three studies observed that
Americans experience more than twice the risk of long waits for
breast or colon cancer care or of dying while they wait for an
organ transplant (RR=2.36, 95% CI 2.09-2.66). These findings
were replicated across externally valid national studies and more
internally valid, metropolitan or provincial/state comparisons.
Socioeconomically vulnerable Canadians are consistently and
highly advantaged on health care access and outcomes compared
to their American counterparts. Less vulnerable comparisons
found more modest Canadian advantages. The Affordable Care
Act ought to be fully supported including the expansion of
Medicaid across all states. Canada’s single payer system ought to
be maintained and strengthened, but not through privatization.
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Selection of studies
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This field’s last systematic review searched until December 31,
2002. The following research or gray literature databases were
searched between January 1, 2003 and January 1, 2019: PubMed,
Medline, CINAHL Complete, ProQuest Nursing and Allied Health
Database, EBM Reviews, HealthSTAR, Social Work Abstracts,
Social Services Abstracts, ProQuest Sociology Collection,
ProQuest Dissertations and Theses, Conference Proceedings
Citation Indexes − Science and Social Sciences & Humanities, and
Google Scholar. Detailed keyword search schemes are summarized as follows: (Canada or any of 13 provinces or territories) and
(United States or USA or any of 50 states) and (health care access
or treatment or outcome or survival or for example, asthma or heart
attack or MI or coronary heart disease or CHD or cancer or any of
the most common acute conditions or chronic diseases). Any
observational study of any physical health condition or disease
with an indicated treatment or well-defined outcome was included.
In an effort to find studies specifically about socioeconomically vulnerable subpopulations, the searches were then systematically replicated with addition of the following keyword set: (poverty
or income or socioeconomic factors or health insurance or uninsured). Study exclusion criteria were: (1) published in 2003, but
included in the previous review, (2) opinion surveys of patients or
practitioners, (3) randomized controlled trials as they may not
reflect typical patients or typical care, (4) national mortality studies
that confound disease incidence and survival or (5) studies of mental health. For scholarly and policy reasons we think that mental
health care warrants a separate research review; one we are
presently scoping.21,22 Searches were augmented with bibliographic reviews of retrieved studies. Searches of their authors were also
performed. Three reviewers, one an experienced academic librarian, independently searched for eligible studies. When two reviewers suggested eligibility based on study titles and abstracts, it was
included. If in the review of full study manuscripts any research
team member suspected ineligibility, a consensus decision was
reached after discussion. Twenty-five studies were so selected.23-47
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This field’s first systematic review of 18 studies of health care
among patients with diverse acute conditions or chronic diseases
found few differences between both countries on relevant outcomes
such as mortality.8 As none of the primary studies accounted for
socioeconomic factors, neither could the review. More fundamentally though, many studies of that era could not even account for
between-country differences on disease severity. For example, at
that time no Canadian cancer registry yet included disease stage at
diagnosis. Hence, Canada-USA cancer care comparisons could not
account for such basic case-mix differences. However, this early
review made an extraordinarily valuable heuristic contribution. It
clarified the fact that this field’s extant research was not yet rigorous enough to inspire confident judgements about the relative
effectiveness of Canadian versus American health care. It also
highlighted future research that would be needed to make confident decisions.
Nearly a decade later, a greater number of similarly limited
studies of diverse Canadian and American patients were systematically reviewed.9 Fourteen studies observed Canadian advantages,
5 observed USA advantages and 19 were null. Overall, the risk of
mortality was estimated to be 5% lower among Canadians. Such
inconsistent and modest between-country differences could as
plausibly be due to unaddressed confounding or effect modifications as to true health care differences. This review team also found
that the one disease for which results consistently favored
Canadians was end-stage renal disease. The high costs and
resource utilization associated with this chronic condition are
much better managed in Canada’s predominantly not-for-profit
system. This is another element of patient case-mix − chronic diseases versus acute conditions − to consider in future syntheses.
The third research synthesis, a meta-analysis of 8 breast cancer
survival studies, one of which was stage-adjusted, did incorporate
socioeconomic factors.10 Among low-income women, it estimated
a Canadian survival advantage of 14% (sample-adjusted rate ratio
[RR]=1.14, 95% CI 1.13-1.15) that was even larger among
younger women who were not yet Medicare eligible in the USA
(RR=1.21, 95% CI 1.17-1.25). No between-country survival difference was observed among its aggregated middle- and highincome groups. However, its ecologically-defined low-income
neighborhoods were typically places where only 10% to 15% of
the residents were poor. None studied sociologically well-known
high poverty neighborhoods where 30% to 40% or more of the
people were poor.11,12 This research synthesis recommended future
primary studies in such vulnerable places and accounting for other
aspects of place such as residence in large urban, small urban or
rural places as they represent very different health care endowments in both countries.
This review aims to systematically update this field’s knowledge, incorporating as many of the previous reviewers’ suggestions
as its primary studies allow. We posed three questions:
(1) Compared to Americans, are Canadians advantaged on health
care access and outcomes?
(2) Are Canadian advantages larger among socioeconomically
vulnerable people?
(3) Are Canadian advantages larger among people with chronic
diseases than acute conditions?

review.13-15 Methodological guidance of teams of researchers and
knowledge users on both sides of the Canada-USA border allowed
us to gain efficiencies and compress the review time period.16,17
The rapid systematic review included a classical, but also streamlined meta-analysis to gain specific knowledge about the relative
effectiveness of health care in Canada and the USA, particularly
among socioeconomically vulnerable subpopulations with specific
acute conditions or chronic diseases.18-20
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Previous research syntheses

Materials and Methods

Traditional interdisciplinary methodological frameworks were
used to guide the process and presentation of this systematic
[page 2]

Meta-analysis

The unit of analysis for this meta-analysis was the unique
hypothesis test. Between-country comparisons were observed for
treatment access or outcomes among overall samples or socioeconomically vulnerable subsamples. These were treated as independent hypotheses. Each study could contribute only once to each
hypothesis test. If a primary study provided three outcomes all
related to the same hypothesis, for example, 1, 3 and 5-year survival among colon cancer patients living in poverty, the three estimated survival rate ratios would be pooled so that that study would
contribute one data point for that meta-analytic hypothesis test. A
total of 34 such independent study findings were included in this
meta-analysis.
Treatment or survival rate ratios, odds ratios, hazard ratios or
similar measures of effect estimated primary study relative risks

[Journal of Public Health Research 2019; 8:1479]
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advancement over such previously reviewed studies, nearly all of
the cancer analyses were minimally case-mix adjusted for age and
stage of disease at diagnosis. Otherwise, the diverse acute conditions or chronic diseases displayed in the top of Table 4 seem a fair
representation of interesting and important health care indicators
studied over the life course from infancy to older adulthood.
Twenty-four outcomes combined effects for women and men,
treating gender as a covariate. Ten outcomes were of women only,
while there were no exclusively male outcomes. Seven studies
accounted for race/ethnicity, but again, only as a covariate. No specific racialized/ethnic group outcomes were reported.
A quarter of the study outcomes were nationally representative. Another 60% or so were representative of single or multiple
provinces and states. The remainder were single metropolitan area
investigations. Research designs were predominantly historical
cohorts (82%) initiated in the 1990s (65%). Aggregated study samples ranged from 62 to 120,117, the median being 2,306 participants. About two-thirds of the study outcomes were based on quite
powerful samples of 1,000 to 25,000 or more, emphasizing external validity. Another third of the outcomes were based on smaller
and better controlled investigations, emphasizing internal validity.
Consistent with the prevalent use of well-supported and validated
administrative data, most of the analyses lost less than 1% of their
original participants to follow-up. Three outcomes of one study
reported differential losses (2.5% in Canada vs 5.5% in the
USA),34 but such only made these comparisons conservative. As
mentioned, all the primary analyses accounted for at least two
covariates. Typically, they accounted for 4 to 9 such comorbid factors or biomarkers. Finally, 10 measures of treatment access and 24
treatment outcome measures, typically survival, were represented.
In fact, we think that most, if not all, of the mortality outcomes
were actually measures of survival. As the studies typically followed a well-defined diagnostic group in a similar manner, survival is probably not confounded by condition or disease incidence. The primary studies included in this review seem more rigorous than previously reviewed studies as a larger portion of the
studies used well-controlled cohort designs.
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(RR). Natural logarithms of study RRs were weighted by their
inverse variances, computed from standard errors (1/SE2) so that
larger, more precise studies carried more weight. Standard errors
were estimated from study statistics, generally from reported 95%
CIs. Such precision-weighted effects were then pooled within
domains of interest using weighted regression models. Pooled RRs
within 95% CIs were calculated from regression statistics, as were
tests of heterogeneity (χ2) and meta-analytic between-groups comparisons (z). All statistical significance decisions were made at the
α criterion of 0.05. For ease of interpretation, all RRs greater than
1.00 indicated a Canadian advantage, while those less than 1.00
indicated an American advantage. Study hypotheses were so tested: (1) Compared to Americans, Canadians are advantaged on
health care access and outcomes (primarily survival). (2) Canadian
advantages are larger among socioeconomically vulnerable people.
(3) Canadian advantages are larger among people with chronic diseases than acute conditions. Meta-analytic hypotheses were independently tested and cross-validated by two analysts.
As expected, given the sociodemographic, geographic, clinical
and methodological variability, the 34 independent primary study
outcomes demonstrated substantial heterogeneity (χ2 [33] =
26,565.00, P<0.05) around a hypothetically supportive precisionadjusted pooled Canadian advantage of 13% (RR=1.13, 95% CI
1.12-1.14). Our central hypothesized moderators of socioeconomic
factors and disease chronicity aim to explain such variability. In
fact, we expected and found substantial effect homogeneity within
specific groups of interest after accounting for disease and socioeconomic status. For example, focusing on guideline-based treatment access among women living in poverty with breast cancer,
the 3 relevant study outcomes demonstrated essentially no heterogeneity (χ2 [2] = 0.01, P=0.99) around a precision-adjusted pooled
Canadian advantage of 75% (RR=1.75, 95% CI 1.64-1.87).45-47
Therefore, the potential moderating effects of study characteristics
were explored with fixed-effects meta-regressions. In addition to
hypothetically noted characteristics, this streamlined meta-analysis
explored the following patient, contextual and research design
characteristics: age, gender, ethnicity, health insurance status,
large/small urban/rural places, historical/prospective cohort,
cohort timeframe, study sample sizes, geographic sampling frames
(national/provincial-state/metropolitan), clinic or populationbased, primary/administrative data, number of analytic comorbid
factors or biomarkers, and follow-up rates. Study characteristics
were abstracted independently from full primary study
manuscripts by two reviewers. After discussion and resolution of
discrepancies their agreement was 100%.

Results

Sample description

Descriptive details of the 19 overall population and 15 socioeconomic subpopulation study outcomes are respectively presented
in Tables 1-3. Socioeconomically vulnerable subpopulations
included those who lived in poverty in Canada and the USA and/or
were uninsured or inadequately insured in the USA. All unique
study hypotheses, based on unique subsamples, treatments or outcomes, are displayed along with their within-study pooled RRs.
Descriptive summaries of participant and study characteristics are
displayed in Table 4. Half of the study outcomes were of cancer,
most prevalently breast or colon cancer. This is perhaps not surprising given the comprehensiveness and validity of contemporary
cancer registration in both countries. Representing a distinct

Meta-analytic findings

In support of the first hypothesis, 25 study observations indicated Canadian health care advantages, 3 observed USA advantages and 6 were null. The chances of receiving health care in a
timely manner and surviving were estimated to be 13% greater
among Canadians (RR=1.13, 95% CI 1.12-1.14) than Americans.
Meta-analytic findings related to hypotheses two and three are displayed in Table 5. In support of hypothesis two, all 15 observations
of socioeconomically vulnerable people indicated Canadian
advantages, though 1 only approached statistical significance.
Their chances of receiving better health care were estimated to be
36% greater than their American counterparts (RR=1.36, 95% CI
1.35-1.37). This Canadian advantage was significantly and substantially larger than that estimated with 19 overall samples of
patients; z=48.47, P<0.05: 10 observed Canadian advantages, 3
USA advantages and 6 were null (RR=1.09, 95% CI 1.08-1.10).
Furthermore, statistically and practically larger Canadian advantages were replicated among socioeconomically vulnerable
patients with acute conditions (RR=1.14 vs RR=1.03) and chronic
diseases (RR=1.37 vs RR=1.12). Because one of us (KMG) produced 12 of the 15 socioeconomically vulnerable population comparisons we performed a sensitivity analysis. The pooled effect of
KMG’s research group (RR=1.35, 95% CI 1.34-1.36) did not differ
significantly from that of three other research groups (RR=1.38,
95% CI 1.35-1.41), z=0.19, P=0.85. Hypothesis three was also
consistently supported. Within overall Canada-USA comparisons

[Journal of Public Health Research 2019; 8:1479]
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Table 1. Description and outcomes of studies included in the rapid review and meta-analysis: Overall Canada and USA comparisons
(acute conditions).
Reference

Clinical population, ages
Places
Cohort years
Other characteristics

Research design
Selection
Analytic samples
Covariate adjustmentsa

Outcome
Canada vs USA adjusted rates
Risk ratiob
95% confidence interval

Acute decompensated heart failure
Lai et al. 2016

ADHF in ED, 18 or older
Ottawa, ON & Rochester, MN 2010
1 & 1 ED

Historical cohort
Population, health records
156 & 165
Age, gender, 5 comorbidities & 3 biomarkers

30-day mortality
5.1% vs 9.7%
OR = 1.99
95% CI: 0.83, 4.78

Acute myocardial infarction
Hospitalized with AMI, 65 or older
Ontario & USA
1998 to 2001
All Medicare covered

Historical cohort
Random, administrative data
5,634 & 38,886
Age, gender, 7 comorbidities & 7 biomarkers

30-day risk-standardized mortality
16.6% vs 17.3%
SMR = 1.05
95% CI: 0.99, 1.11c

Ko et al. 2007

//

//

1-year risk-standardized mortality
27.7% vs 31.9%
SMR = 1.15
95% CI: 1.06, 1.25

Ko et al. 2007

//

//

Historical cohort
Population, administrative data
41,492 & 78,625
Age & gender

al

Pediatric appendectomy, less than 18
Canada (not Quebec) & USA
2004 to 2010
All insurers

3-year risk-standardized mortality
40.3% vs 45.9%
SMR = 1.14
95% CI: 1.05, 1.23
[SMRpooled = 1.08, 95% CI: 1.06, 1.10]

Perforated appendicitis
27.3% vs 26.7%
RR = 0.98
95% CI: 0.96, 1.00

ci

Cheong & Emil 2014

us

Appendicitis

e

on

ly

Ko et al. 2007

Exacerbated COPD in ED, M 70
Canada & USA
1999 to 2001
5 & 24 EDs, 3 provinces & 15 states

Norregaard et al. 2003
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Rowe et al. 2008

Acute asthma in ED, ages 2 to 54
Canada & USA
1996 to 1998
8 & 69 EDs, 4 provinces & 22 states

om

Rowe et al. 2007

m
er

Asthma

Unilateral cataract surgery, 50 or older
Manitoba & USA
1993 to 1994
12 & 75 ophthalmology practices

Prospective cohort
Population, primary data
136 & 2,198
Age, gender, race, income & 4 biomarkers

2-week ED relapse
nd
OR = 0.63
95% CI: 0.30, 1.43

COPD
Prospective cohort
Population, primary data
58 & 291
Age, gender, race, income, BMI
4 comorbidities & 6 biomarkers

2-week ED relapse
nd
RR = 0.30
95% CI: 0.01, 6.09

Cataract surgery
Prospective cohort
Consecutive, primary data
111 & 570
Age, gender, general health status
1 comorbidity & 3 biomarkers

4-month visual functioning
nd
OR = 1.00
95% CI: 0.96, 1.26

Gastroschisis
Youssef et al. 2003

Simple gastroschisis, newborns
Canada & USA
2003 to 2013
16 & 345 NICUs

Prospective cohort
Population, registry & administrative
584 & 4,502
Age, gender
3 comorbidities & 3 biomarkers

Inpatient mortality
1.4% vs 3.4%
RR = 2.43
95% CI: 1.27, 4.65

Youssef et al. 2003

Complex gastroschisis

111 & 714

10.8% vs 9.3%
RR = 0.86
95% CI: 0.51, 1.46
[RRpooled = 1.34, 95% CI: 1.12, 1.60]

ADHF, acute decompensated heart failure; AMI, acute myocardial infarction; BMI, body mass index; CT, census tract; CABG, coronary artery bypass graft; COPD, congestive obstructive pulmonary disease; ED, emergency
department; ESRD, end-stage renal disease; HR, hazard ratio; IMR, infant mortality ratio; M, mean; Mdn, median; MMR, maternal mortality ratio; nd, no data; NICU, neonatal intensive care unit; OR, odds ratio; PM, person
months; PY, person years; RR, rate ratio; SEER, Surveillance, Epidemiology and End Results program; SES, socioeconomic status; SMR, standardized mortality ratio. aPotential confounds that were accounted for by sample restriction, matching or mathematical/regression modeling. bRisk ratios were adjusted in regressions or directly standardized. Risk ratios greater than 1.00 indicate a Canadian advantage while those less than 1.00
indicate a USA advantage. cP = 0.10. dUnadjusted rates.
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Table 2. Description and outcomes of studies included in the rapid review and meta-analysis: Overall Canada and USA comparisons
(chronic disease).
Reference

Clinical population, ages
Places
Cohort years
Other characteristics

Research design
Selection
Analytic samples
Covariate adjustmentsa

Outcome
Canada vs USA adjusted rates
Risk ratiob
95% confidence interval

Cancer

Warren et al. 2011

Stephenson et al. 2017

Cystic fibrosis, all ages
Canada & USA
2009 to 2013
All insurers
//

us

Stephenson et al. 2017

CABG surgery, 21 or older
Canada & USA
1997 to 2000 4 & 5 hospitals

Ko et al. 2005

Ko et al. 2005

N

on

Eisenberg et al. 2005

Peritoneal dialysis, M 54 & 53
Canada & USA
1990 to 1993
Kidney failure, 10 & 4 centers

ci
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End-stage renal disease
Prospective & historical cohorts
Population, registry-based 19 & 43
Age, ESRD cause
National MMR & IMR
Historical cohort
Population, registry-based 5,773 & 70,708
Age, gender, race, ESRD cause,
Time on dialysis, year of transplant
Prospective cohort
Consecutive, primary data 578 & 102
Age, gender, 2 comorbidities
2 biomarkers & background mortality
Heart disease
Historical cohort
Consecutive, administrative data
7,319 & 4,698
Age, gender, previous CABG, elective or non- &
7 comorbid conditions
Historical cohort
Population, administrative data
8,180 & 28,521
Age, gender, 5 comorbidities & 5 biomarkers
//

m
er

Quinn et al. 2010

om

Kim et al. 2006

Hemodialysis, M 27 & 34
Toronto, ON & USA
2000 to 2013 & 1990 to 2011
Pregnant women with ESRD
Kidney transplant recipients, 18 or older
Canada & USA 1991 to 1998
End-stage renal diseas

-c

Hladunewich et al. 2014

Received home health care
57.5% vs 20.1%
RR = 2.86
95% CI: 2.77, 2.95
5-year survival
nd
OR = 0.94
95% CI: 0.68, 1.29
5-year relative survival
57.1% vs 52.4%
RR = 1.09
95% CI: 1.05, 1.13
Received palliative chemotherapy
20.6 vs 10.9 patients per 100 PM
95% CI: 0.36, 0.78 RR = 0.53

ly

Gupta et al. 2009

Historical cohort
Population, registry-based
8,643 & 16,858
Age, stage & health insurance
Historical cohort
Random, registry-based
930 & 1,014
Age, stage & gender
Historical cohort
Population, registry-based
3,262 & 8,399
Age, gender & mortality causes
Historical cohort
Population, registry-based
Age, sex, income & urbanity
Cystic fibrosis
Historical cohort
Population, registry-based
4,662 & 32,699
Age, gender, race, BMI, 3 comorbidities & 5 biomarkers
//

on

Gorey et al. 2011

Advanced lung cancer, 65 or older
Ontario & USA (SEER)
2001 to 2005
All Medicare covered
Colon cancer, 25 or older
Toronto, ON & San Francisco, CA
1996 to 2006
All income groups
Upper aerodigestive tract cancer, M 64 & 62
Ontario & USA (SEER)
1999 to 2006
Most recent of 6 cohorts
Non-small cell lung cancer, 65 or older
Ontario & USA (SEER)
Last 5 months of life

e

Bremner et al.2015

Heart failure, hospitalized, 65 or older
Ontario & USA
1998 to 2001
All Medicare covered
//

Stell et al. 2004

Liver transplant recipients, Mdn 52 & 50
Canada & USA 2000
First cadaveric transplant

Stell et al. 2004

//

Liver disease
Historical cohort
Population, registry-based
308 & 3,364
Age, sex, 4 comorbidities & 4 biomarkers
//

Survival
50.9 & 40.6 median survival age
HR = 1.52
95% CI: 1.23, 1.85
Received lung transplant
10.3% & 6.5%
RR = 1.58
95% CI: 1.44, 1.74 RR = 0.53

Live birth rate
84.4% & 61.4%d
HR = 1.37
95% CI: 1.04, 1.80
Post-transplant mortality
29.8 & 40.9 deaths per 1,000 PYd
HR = 1.35
95% CI: 1.24, 1.47
Peritoneal dialysis mortality
98.5 & 157.9 deaths per 1,000 PYd
HR = 1.93
95% CI: 1.13, 3.28
In-hospital mortality
nd
OR = 0.92
95% CI: 0.62, 1.35
30-day mortality
10.7% & 8.9%
SMR = 0.83
95% CI: 0.77, 0.89
1-year mortality 32.3% & 32.2%
SMR = 1.00 95% CI: 0.96, 1.04
[SMRpooled = 0.96, 95% CI: 0.95, 0.98]
1-year post-transplant survival
91.3% & 88.0%
RR = 1.04
95% CI: 0.99, 1.09c
Wait-list mortality
3.1 vs 7.6 deaths per million population
RR = 2.43
95% CI: 1.43, 4.14
[RRpooled = 1.05, 95% CI: 1.03, 1.07]

ADHF, acute decompensated heart failure; AMI, acute myocardial infarction; BMI, body mass index; CT, census tract; CABG, coronary artery bypass graft; COPD, congestive obstructive pulmonary disease; ED, emergency
department; ESRD, end-stage renal disease; HR, hazard ratio; IMR, infant mortality ratio; M, mean; Mdn, median; MMR, maternal mortality ratio; nd, no data; NICU, neonatal intensive care unit; OR, odds ratio; PM,
person months; PY, person years; RR, rate ratio; SEER, Surveillance, Epidemiology and End Results program; SES, socioeconomic status; SMR, standardized mortality ratio. aPotential confounds that were accounted
for by sample restriction, matching or mathematical/regression modeling. bRisk ratios were adjusted in regressions or directly standardized. Risk ratios greater than 1.00 indicate a Canadian advantage while those
less than 1.00 indicate a USA advantage. cP = 0.10. dUnadjusted rates.
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Table 3. Description and outcomes of studies included in the rapid review and meta-analysis: Comparisons of socioeconomically vulnerable people in Canada and the USA.
Reference

Clinical population, ages
Places
Cohort years
Other characteristics

Research design
Selection
Analytic samples
Covariate adjustmentsa

Outcome
Canada vs USA adjusted rates
Risk ratiob
95% confidence interval

Acute conditions: Appendicitis
Cheong & Emil 2014

Pediatric appendectomy, less than 18
Canada (not Quebec) & USA
2004 to 2010
Uninsured in USA

Historical cohort
Population, administrative data
41,492 & 12,344
Age & gender

Perforated appendicitis
27.3% vs 31.2%
RR = 1.14
95% CI: 1.05, 1.23

Bremner et al. 2015

Advanced lung cancer, 65 or older
Ontario & USA (SEER)
2001 to 2005
Lowest Mdn income three-fifths
Breast cancer, 25 or older
Ontario & California
1996 to 2014
Very high poverty neighborhoodsc
Publicly or uninsured in USA

Historical cohort
Population, registry-based
3,071 & 5,215
Age, stage & health insurance
Historical cohort
Random, registry-based
315 & 2,100
Age, stage, grade, tumor size & hormone receptor status
315 & 974

HR+ breast cancer, 25 or older
Ontario & California
1996 to 2011
Very high poverty neighborhoodsc
Node negative, low or
Intermediate grade breast cancer

Historical cohort
Random, registry-based
216 & 993
Age & hormone receptor status
85 & 624
Age, stage, grade & tumor size

Chronic diseases: Cancer

Gorey et al. 2015a

ly

on

e

Gorey et al. 2015a

us

Gorey et al. 2017

al

Gorey et al. 2017

Uninsured in USA

85 & 56

Gorey et al. 2015b

Non-metastasized colon cancer, 25 or older
Ontario & California
1996 to 2011
Very high poverty neighborhoodsc
All poverty groups
Publicly or uninsured in USA

om

-c

Historical cohort
Random, registry-based
692 & 1,496
Age, gender & stage
2,060 & 2,509

Historical cohort
Random, registry-based
289 & 975
Age, stage & grade
289 & 173

Gorey et al. 2013

Very high poverty neighborhoodsc

78 & 241

Gorey et al. 2013

Un- or Medicaid-insured in CA

78 & 54

Gorey et al. 2013

Very high poverty neighborhoodsc

55 & 229

Gorey et al. 2013

Un- or Medicaid-insured in CA

55 & 57
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Gorey et al. 2013

Colon cancer, women, 25 or older
Ontario & California
1996 to 2011
Very high poverty neighborhoodsc
Un- or Medicaid-insured in CA

N

Gorey et al. 2013
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Gorey et al. 2015a

Gorey et al. 2015b

180-day survival
66.0% vs 61.5%
RR = 1.07
95% CI: 1.04, 1.10
Received optimum cared
38.1% vs 23.1%
RR = 1.65
95% CI: 1.39, 1.96
38.1% vs 18.0%
RR = 2.12
95% CI: 1.76, 2.56
[RRpooled = 1.87, 95% CI: 1.77, 1.98]
Received hormone therapy
68.2% vs 41.2%
RR = 1.65
95% CI: 1.44, 1.89
64.0% vs 44.5%
Received optimum caree
RR = 1.44
95% CI: 1.16, 1.79
64.0% vs 33.8%
RR = 1.89
95% CI: 1.31, 2.72
[RRpooled = 1.62, 95% CI: 1.54, 1.70]
10-year survival
38.2% vs 33.3%
RR = 1.15
95% CI: 1.02, 1.30
38.7% vs 32.8%
RR = 1.18
95% CI: 1.09, 1.28
[RRpooled = 1.17, 95% CI: 1.13, 1.21]
7-year survival
44.6% vs 38.4%
RR = 1.16
95% CI: 1.00, 1.35
44.6% vs 30.7%
RR = 1.45
95% CI: 1.14, 1.85
[RRpooled = 1.23, 95% CI: 1.17, 1.29]
Received adjuvant chemotherapy
Stage III: 45.1% vs 43.6%
RR = 1.03
95% CI: 0.83, 1.28
45.1% vs 30.2%
RR = 1.49
95% CI: 1.00, 2.25
Waited 60 days or more for chemotherapy
Stage II or III: 20.0% vs 37.7%
RR = 1.89
95% CI: 1.14, 3.13
20% vs 59.8%
RR = 2.99
95% CI: 1.82, 5.00
[RRpooled = 1.35, 95% CI: 1.25, 1.45]
Continued on next page.
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(RR=1.12 vs RR=1.03) and within socioeconomically vulnerable
populations (RR=1.37 vs RR=1.14), Canadian advantages were
larger among people with chronic diseases. Finally, after accounting for socioeconomic factors and disease chronicity, no other primary study characteristic was significantly associated with
Canada/USA RRs.

than Americans. That estimate was more unequivocal and larger
than previous review estimates that were based on less internally
valid research designs. The most typical primary studies included
in this review were historical cohorts that accounted for 4 to 9
covariates in analyzing the experiences of 1,000 to 25,000 patients,
more than 99% of whom were available for assessment at followup. As with primary research however, such a meta-analytic main
or average effect can be misleading. Therefore, we advanced and
found much support for a meta-analytic country by socioeconomic
status interaction. This clearly demonstrated that Canadian advantages were significantly larger among those living in poverty or
those who were otherwise socioeconomically vulnerable such as
the uninsured or inadequately insured.
Among patients who lived in high poverty neighborhoods, it
was estimated that the chances of Canadians receiving indicated

Discussion

This study found that Canadians with any number of acute
health conditions or chronic diseases are significantly more advantaged on health care access and outcomes compared to their counterparts in the USA. It estimated that the chances of Canadians
receiving indicated treatments and surviving were 13% greater

Research design
Selection
Analytic samples
Covariate adjustmentsa

Gorey et al. 2011

Colon cancer, 25 or older
Toronto, ON & San Francisco, CA
1996 to 2006
Lowest income (%) third

Historical cohort
Random, registry-based
231 & 247
Age, stage & gender

5-year survival
nd
OR = 2.51
95% CI: 1.52, 4.15

Gorey et al. 2011

1996 to 2002
Lowest income (%) two-thirds

291 & 273

Gorey et al. 2010a

Node negative breast cancer, 25 or older
Ontario & California
1988 to 2006
Lowest income (%) tenth
Lowest income (%) third

Received adjuvant chemotherapy
Stage II or III: 57.3% vs 34.3%
RR = 1.67
95% CI: 1.06, 2.64
15-year survival
50.2% vs 30.2%
RR = 1.66
95% CI: 1.00, 2.76
Received adjuvant radiation therapy
42.7% vs 24.4%
RR = 1.75
95% CI: 1.21, 2.53
5-year survival
80.3% vs 66.3%
RR = 1.21
95% CI: 0.98, 1.50g
Received hormone therapy
55.1% vs 31.2%
RR = 1.77
95% CI: 1.12, 2.79
Received adjuvant radiation therapy
60.3% vs 36.0%
RR = 1.68
95% CI: 1.12, 2.54
Waited 60 days or more for treatment
4.7% vs 9.7%
RR = 2.08
95% CI: 0.87, 5.00g
[RRpooled = 1.75, 95% CI: 1.49, 2.05]
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Historical cohort
Random, registry-based
36 & 41
Age, stage & tumor size
105 & 126

Breast cancer, 25 or older
Ontario & California
1998 to 2006
High poverty neighborhoodsf
//

Historical cohort
Random, registry-based
50 & 50
Age, race & stage
49 & 49

N

Gorey et al. 2010b

om

Gorey et al. 2010b

-c

Gorey et al. 2010a

on

Clinical population, ages
Places
Cohort years
Other characteristics

on

Reference

ly

Table 3. Continued from previous page.

Gorey et al. 2009

Gorey et al. 2009

Stephenson et al. 2017

Node positive breast cancer, 25 or older
Ontario & California
1998 to 2000
Lowest income (%) third
Non-metastasized breast cancer
Windsor, ON & Modesto, CA

Cystic fibrosis, all ages
Canada & USA
2009 to 2013
Uninsured in USA

Historical cohort
Random, registry-based
95 & 94
Age & stage
110 & 163

Cystic Fibrosis
Historical cohort
Population, registry-based
4,662 & 205
Age, gender, race, BMI
3 comorbidities & 5 biomarkers

Outcome
Canada vs USA adjusted rates
Risk ratiob
95% confidence interval

Survival
nd
HR = 4.35
95% CI: 2.70, 7.14

BMI, body mass index; HR = hazard ratio; HR+, hormone receptor positive; Mdn, median; nd, no data; OR, odds ratio; RR, rate ratio; SEER, Surveillance, Epidemiology and End Results program; SES, socioeconomic
status. All income measures were ecological, census tract (CT)-based. All of the Ontario-California comparisons by Gorey et al. also accounted for place by sample stratification (large urban places, small urban places
or rural places) and for purchasing power differences (adjustments for Canadian-USA dollar and US Census Bureau poverty and Statistic Canada low-income definition differences). aPotential confounds that were
accounted for by sample restriction, matching or mathematical/regression modeling. bRisk ratios were adjusted in regressions or directly standardized. Risk ratios > 1.00 indicate a Canadian advantage while those <
1.00 indicate a USA advantage. c30% or more of the household were poor in the USA compared to similarly low-income neighborhoods in Canada. dDiagnosed early with node negative disease and received breast conserving surgery followed by radiation therapy. eReceived breast conserving surgery within two months of diagnosis and adjuvant radiation therapy with four months of surgery. f20% or more of the household were poor
in the USA compared to similarly low-income neighborhoods in Canada. g P<0.10.
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ance coverage in the USA as the primary explanation for this
study’s findings. It clearly indicts the USA for the largely inadequate health insurance coverage it provides its underclass,11
including those who live in poverty or near poverty as well as the

Table 4. Participant and study characteristics: 34 study outcomes
included in the meta-analysis.

al
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Acute conditions or chronic diseases studied
Acute heart failure/myocardial infarction
Appendicitis
Asthma
COPD (urgent care)
Cataract surgery
Gastroschisis (NICU care)
Cancera
Kidney failure/ESRD
Cystic fibrosis
Heart failure/heart disease
Liver disease
Participant ages
Adults 18 to 25 or older
Older adults 50 to 65 or older
All people (children and adults)
Children less than 18 years of age
Infants
Sampling frame: Canada vs USA
Single province vs single stateb
Nation vs nationc
Single provinced vs nationc
Three or more provinces and states
Single metropolitan arease
Single metropolitan areae vs nation
Cohort initiation
1980s
1990s
2000s
2010s
Research design
Retrospective cohortf
Prospective cohortg
Aggregate analytic sampleh
< 100
00 to 999
1,000 to 24,999
≥ 25,000
Number of covariatesi
2 or 3
4 to 9
10 to 15
Study outcome
Treatment accessj
Survival/mortality/failure, < 1 year
Survival/mortality/failure, 1 to 5 years
Survival/mortality/failure, > 5 to 15 years
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treatments and surviving were 36% greater than Americans. That
estimate was essentially unequivocal across all the reviewed studies and was larger than a previous meta-analytic estimate based on
less prevalently poor neighborhoods. Recalling that such a 36%
differential is implicated across most common health conditions
and diseases over the lives of millions of impoverished Canadians
and Americans, its population-level significance is clear. In addition to accounting for socioeconomic factors most of these primary
studies also accounted for key personal and contextual case-mix
differences between Canada and the USA, notably disease severity
and health care service endowments in diverse large to small urban
or rural places. We consider the robustness of the observed
Canadian advantage to be our review’s most provocative scholarly
and policy-significant finding. As with primary research, we think
that the interpretation of significant interaction effects or important
effect modifications ought to take precedence in synthetic
research. Therefore, we think four more interpretive adjuncts are in
order. First, larger Canadian advantages were replicated among
socioeconomically vulnerable patients with acute conditions and
chronic diseases, representing a multiplicative Canadian advantage
among those living in poverty with chronic diseases. Such patients
probably had multiple experiences with their respective health care
system over several years. In other words, it seems that the longer
patients were in contact with their respective Canadian or
American health care systems, the larger were their respective
advantages or disadvantages. Second, three studies included four
assessments of wait-lists, estimating that the exemplary risks of
experiencing relatively long waits for adjuvant cancer care or of
dying while waiting for a liver transplant were much greater in the
USA (RRs ranged from 1.89 to 2.99, precision-weighted RR=2.36,
95% CI 2.09-2.66) than in Canada.40,44,47 This evidence stands in
stark contrast to prevalent contemporary political rhetoric. Third,
all this field’s synthetic evidence strongly suggests a dose-response
relationship between socioeconomic vulnerability and Canadian
advantages. It seems, therefore, that Canada’s single payer health
care system causally provides much better health care than does
the USA’s multiple payer system that still leaves millions uninsured or inadequately insured. The Canadian health care system’s
most pronounced evidence-based advantages are clearly among
those who live in poverty who consistently experience much better
health care compared to impoverished Americans. In short, the
more socioeconomically vulnerable a person is the more protective
a single payer health care system is likely to be.
The fourth interpretive adjunct arose serendipitously in our
systematic search for eligible studies. We retrieved 8 withinCanada studies of socioeconomic factors and cancer care.48-55
Though ineligible for this review, these studies were very interesting. One observed a modest indirect low-income-care association.
Five others observed similar trends, but were not statistically significant and two others were null. The pooled precision-weighted
estimate was minuscule (RR=0.97, 95% CI 0.95-0.99). We identified more than 100 such within-USA studies nearly all of which
observed the well-known, large American socioeconomic-care gradient. Six studies that were included in this review, but that also
observed typically very low-income or poverty associations with
cancer care in both Canada and the USA allowed for a controlled,
precision-weighted synthetic comparison.31,41,43,45-47 A large disadvantage of being poor was observed in the USA (RR=0.73, 95% CI
0.71-0.75) while no such association was observed in Canada
(RR=0.99, 95% CI 0.96-1.02), z=14.44, P<0.05. Such withincountry observations clarify the between-country comparisons.
Given the intimate relationship between low socioeconomic status
and health insurance inadequacy in the USA,56-58 but not in
Canada, the pattern resolutely identifies inadequate health insur[page 8]

N.

%

2
2
1
1
1
1
17
3
3
2
1

5.9
5.9
2.9
2.9
2.9
2.9
50.0
8.8
8.8
5.9
2.9

21
6
4
2
1

61.8
17.6
11.8
5.9
2.9

10
9
6
4
4
1

29.4
26.5
17.6
11.8
11.8
2.9

2
22
6
4

5.9
64.7
17.6
11.8

28
6

82.4
17.6

3
10
13
8

8.8
29.4
38.2
23.5

12
13
9

35.3
38.2
26.5

10
9
8
7

29.4
26.5
23.5
20.6

COPD, congestive obstructive pulmonary disease; ESRD, end-stage renal disease; NICU, neonatal intensive care unit. aCancer of the breast (7), colon (6), lung (3) and upper aerodigestive tract (1). bAll were
Ontario and California; Windsor, ON vs Modesto, CA was embedded within one. cFour were based on the
Surveillance, Epidemiology and End Results (SEER) program. dFive were Ontario and one was Manitoba.
eOttawa, ON vs Rochester, MN; four were Toronto, ON vs San Francisco, CA. fUsed secondary/administrative/registry data and all but one were population-based. gMore commonly used primary data and were
either clinic- or population-based.h27 of 34 (79.4%) lost < 1% to follow-up, 5 (14.7%) ≤10%, and 2 did not
report. iPotential confounds accounted for by sample restriction, matching or regression modeling.
j 3 of the 10 treatment measures included some assessment of wait times.
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Though its sampling frame included unpublished sources, this
meta-analytic sample ultimately included only published studies.
One may legitimately wonder if publication bias could be a potent
alternative explanation for its findings. However, this seems
improbable for the following reasons. First, this review’s hypothesis of advantaged Canadian health care specific to socioeconomically vulnerable patients was not the primary hypothetical concern
of the majority of its included studies. In addition, the review
hypothesis of greater Canadian advantages among those with
chronic diseases was not advanced by any of the primary studies.
Secondly, 6 of the 34 study outcomes reviewed were null and one
of the review’s synthetic findings (i.e., 7-study pooled estimate of
acute care of all patients, impoverished to affluent) was nearly null.
Those are precisely the sort of findings one would not readily
expect to retrieve from published studies if publication bias, that is,
a preference to publish significant findings, was potent. This field’s
editorial review boards seem to have been open to publishing null
findings. Third, it seems improbable that publication bias could
account for such a complex pattern of pooled effects moderated by
disease chronicity within patient socioeconomic statuses as is displayed in Table 5. Building upon this modestly funded rapid
review, a well-endowed full systematic review might consider
expanding its gray literature/unpublished research sampling frame.
Future synthetic analysts might start by searching relevant annual
meetings or conferences as well as diverse organizations; grassroots, non-profit or governmental, for the findings of researchers
and/or knowledge users. A snowball survey of such key informants
could bolster the internal and external validity of such a review. In
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Although primary studies in this field were generally not able
to directly account for race/ethnicity, mainly due to the lack of
such data in Canada, some of them replicated their findings by
comparing subsamples of non-Hispanic white patients in the USA
with racially and ethnically diverse Canadian samples.31,41,42,44-46
Large Canadian advantages were still observed in these samples,
thereby validating the socioeconomic and health insurance explanations found in this study. But this does not mean that race does
not matter for the following reasons. Each nation has had unique
histories of oppression leaving certain racialized minority groups
relatively more socioeconomically vulnerable: Indigenous First
Nations, Inuit and Métis people in Canada and African Americans
in the USA. Racialized disparities in health and health care clearly
persist in both countries, but they seem relatively muted in
Canada.59-61 In fact, the phenomenon known as the Hispanic paradox, that is − the health protective effects of being Hispanic despite
living in poverty − may be stronger in Canada.62 The Indigenousnon-Hispanic white divide, however, seems significantly wider in
Canada. Precisely how specific racialized group statuses matter in
Canada-USA comparative heath care is not yet known because
research questions about the unique experiences of racialized subpopulations have not yet been posed. Their future incorporation
would further magnify this field’s human and policy significance.
Notwithstanding the noted incremental strengths of this field’s
research over the past 15 years, it provided predominantly historical cohort-based knowledge about the experiences of Canadian
and American patients in the 1990s to 2000s. Prospective cohorts
were represented more prevalently than in previous reviews, but
remained uncommon. Retrospective studies can be methodologically limited, but we believe that the advancement of confirmed
historical insights is critical in planning future research and policies. Also, we were comforted by the fact that the findings of the

on

Primary research

e

Potential limitations and future research needs

reviewed retrospective and prospective cohorts did not differ significantly. Still, well-controlled prospective cohorts are clearly
needed. A prospective cohort-based research agenda representative
of Canada and the USA emphasizing both internal and external
validity would undoubtedly be quite expensive. However, such an
investment holds the promise of huge knowledge dividends. It
could, for example, provide valuable evidence about the relative
effects of expanding Medicaid (or not) in the USA and the effects
of increasing private options (or not) in Canada. Given the longstanding and often contentious policy debates on health care across
North America, such a well-funded research agenda seems long
overdue.

us

periodically unemployed or underemployed middle-class. Most
regrettably, this indictment holds true in post-Affordable Care Act
America. For example, at the time of this writing, 14 states still had
not fulfilled the Act’s legislative intent to expand Medicaid.

Table 5. Summary of Canada-USA comparative study outcomes.
No. of study outcomes
Overall population comparisons, tot
19
Acute conditions
7
Chronic diseases
12
Socioeconomically vulnerable population comparisons, tot
15
Acute conditions
1
Chronic diseases
14

Study risk ratios
Max.
Median

Pooled
Risk ratio 95% CI

Tot. participants

Min.

438,482

0.30

2.86

1.08

1.09a

1.08-1.10

173,408

0.30

1.99

1.00

1.03bd

1.02-1.04

265,074

0.53

2.86

1.14

1.12cd

1.11-1.13

78,589

1.07

4.35

1.66

1.36a

1.35-1.37

53,836

1.14

1.14

1.14

1.14be

1.05-1.23

24,753

1.07

4.35

1.67

1.37ce

1.36-1.38

Pooled risk ratios with the same superscripts were compared: az = 48.47, bz = 4.79, cz = 41.48, dz = 22.50 and ez = 8.94, all P<0.05.
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addition to collecting data missing from primary study reports it
could facilitate the retrieval of knowledge from unpublished studies that may presently sit in respondent’s file drawers or those of
their colleagues or professional acquaintances. For its admitted
rapidity, this systematic review may be limited in other ways. A bit
more of its practical context may illuminate them. First, this synthesis was essentially unfunded. Second, we began by scoping all
the research on any health status or health care difference between
any two high-income countries. The voluminous results of those
preliminary searches in addition to funding constraints caused us
to focus on a rapid review of the most scholastically interesting,
politically important and feasible research: Health care in Canada
and the USA. We planned exhaustive searches, but of focused
questions within rigorous methodological constraints and a streamlined meta-analysis. We think that these are strengths of this rapid
review. However, in doing so we did not adhere to at least two preferred systematic review and meta-analytic methods. As three
reviewers independently searched for eligible studies, informally
sharing their developing methods throughout the process, we did
not produce a unified flow chart, detailing each step of the information gathering process. Also, reviewers were not blinded to primary study findings. Recall though that each step of the review
process − study selection, data abstraction and meta-analysis − was
initially cross-validated by at least two reviewers. Consensus was
ultimately reached on all selected studies. And 9 of 34 of the primary study outcomes we ultimately included were counter hypothetical, that is, they did not support our review’s central hypothesis of Canadian advantage. For these reasons we believe that our
rapid systematic review approximates the validity of a full systematic review. A better-endowed full systematic review, accomplished by independent reviewers, would be most welcome. Such
systematic replications are the hallmark of sound scientific inquiry,
primary and synthetic.

Conclusions
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This field’s research now seems rigorous enough to support
confident judgements about the relative effectiveness of Canadian
versus American health care, especially among the most socioeconomically vulnerable. Socioeconomically vulnerable Canadians
are consistently and highly advantaged on health care access and
outcomes compared to their American counterparts. Less vulnerable comparisons found more equivocal and more modest Canadian
advantages. The Affordable Care Act ought to be retained, indeed
fully supported, including the envisioned expansion of Medicaid
across all states. When politically achievable, however, single
payer health care would better ensure truly equitable access and
outcomes among America’s diverse population. Canada’s single
payer system ought to be maintained and strengthened where needed, but not through the addition of private tiers.
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